HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
HCW Biologics (NASDAQ: HCWB) reported its Q4 and fiscal year 2024 results, highlighting significant developments in its immunotherapy pipeline. The company received FDA clearance to begin Phase 1 trials for HCW9302 in alopecia areata treatment. A notable licensing agreement with WY Biotech is expected to bring in $7.0 million in June 2025.
Financial highlights include raising $16.3 million in 2024 through various transactions. However, revenues decreased from $1.3 million in Q4 2023 to $394,000 in Q4 2024. The company's net loss increased from $25.0 million in 2023 to $30.0 million in 2024, largely due to legal expenses.
The company faces Nasdaq compliance challenges and must meet listing requirements by April-June 2025. Management acknowledges substantial doubt about continuing operations without additional funding, though financing activities are underway with Maxim Group as Placement Agent.
HCW Biologics (NASDAQ: HCWB) ha riportato i risultati del quarto trimestre e dell'anno fiscale 2024, evidenziando sviluppi significativi nel suo pipeline di immunoterapia. L'azienda ha ricevuto l'approvazione della FDA per avviare gli studi di Fase 1 per HCW9302 nel trattamento dell'alopecia areata. Un accordo di licenza notevole con WY Biotech dovrebbe portare $7,0 milioni a giugno 2025.
I punti salienti finanziari includono la raccolta di $16,3 milioni nel 2024 attraverso varie transazioni. Tuttavia, i ricavi sono diminuiti da $1,3 milioni nel Q4 2023 a $394.000 nel Q4 2024. La perdita netta dell'azienda è aumentata da $25,0 milioni nel 2023 a $30,0 milioni nel 2024, principalmente a causa delle spese legali.
L'azienda affronta sfide di conformità con il Nasdaq e deve soddisfare i requisiti di quotazione entro aprile-giugno 2025. La direzione riconosce un notevole dubbio sulla continuità delle operazioni senza finanziamenti aggiuntivi, anche se sono in corso attività di finanziamento con Maxim Group come agente di collocamento.
HCW Biologics (NASDAQ: HCWB) informó sus resultados del cuarto trimestre y del año fiscal 2024, destacando desarrollos significativos en su pipeline de inmunoterapia. La compañía recibió la autorización de la FDA para comenzar ensayos de Fase 1 para HCW9302 en el tratamiento de la alopecia areata. Se espera que un notable acuerdo de licencia con WY Biotech genere $7.0 millones en junio de 2025.
Los aspectos financieros destacados incluyen la recaudación de $16.3 millones en 2024 a través de varias transacciones. Sin embargo, los ingresos disminuyeron de $1.3 millones en el Q4 2023 a $394,000 en el Q4 2024. La pérdida neta de la compañía aumentó de $25.0 millones en 2023 a $30.0 millones en 2024, principalmente debido a gastos legales.
La empresa enfrenta desafíos de cumplimiento con Nasdaq y debe cumplir con los requisitos de cotización para abril-junio de 2025. La dirección reconoce una duda considerable sobre la continuidad de las operaciones sin financiamiento adicional, aunque están en marcha actividades de financiamiento con Maxim Group como Agente de Colocación.
HCW Biologics (NASDAQ: HCWB)는 2024 회계연도 4분기 및 연간 실적을 보고하며 면역요법 파이프라인의 중요한 발전을 강조했습니다. 이 회사는 HCW9302의 탈모 치료를 위한 1상 시험을 시작할 수 있도록 FDA 승인을 받았습니다. WY Biotech와의 주목할 만한 라이센스 계약은 2025년 6월에 700만 달러를 가져올 것으로 예상됩니다.
재무 하이라이트에는 2024년 다양한 거래를 통해 1,630만 달러를 모금한 것이 포함됩니다. 그러나 수익은 2023년 4분기 130만 달러에서 2024년 4분기 394,000달러로 감소했습니다. 회사의 순손실은 2023년 2,500만 달러에서 2024년 3,000만 달러로 증가했으며, 이는 주로 법적 비용 때문입니다.
회사는 나스닥 준수 문제에 직면해 있으며 2025년 4월에서 6월 사이에 상장 요건을 충족해야 합니다. 경영진은 추가 자금 없이 운영을 지속할 수 있는지에 대한 상당한 의구심을 인정하고 있지만, Maxim Group이 배치 에이전트로서 자금 조달 활동을 진행 중입니다.
HCW Biologics (NASDAQ: HCWB) a annoncé ses résultats du quatrième trimestre et de l'exercice fiscal 2024, mettant en évidence des développements significatifs dans son pipeline d'immunothérapie. L'entreprise a reçu l'autorisation de la FDA pour commencer des essais de Phase 1 pour HCW9302 dans le traitement de l'alopécie areata. Un accord de licence notable avec WY Biotech devrait rapporter 7,0 millions de dollars en juin 2025.
Les points forts financiers incluent la levée de 16,3 millions de dollars en 2024 par le biais de diverses transactions. Cependant, les revenus ont diminué de 1,3 million de dollars au Q4 2023 à 394 000 dollars au Q4 2024. La perte nette de l'entreprise a augmenté de 25,0 millions de dollars en 2023 à 30,0 millions de dollars en 2024, principalement en raison des frais juridiques.
L'entreprise est confrontée à des défis de conformité avec le Nasdaq et doit respecter les exigences de cotation d'ici avril-juin 2025. La direction reconnaît des doutes considérables quant à la continuité des opérations sans financement supplémentaire, bien que des activités de financement soient en cours avec Maxim Group en tant qu'agent de placement.
HCW Biologics (NASDAQ: HCWB) hat seine Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 veröffentlicht und dabei bedeutende Entwicklungen in seiner Immuntherapie-Pipeline hervorgehoben. Das Unternehmen erhielt die Genehmigung der FDA, um Phase-1-Studien für HCW9302 zur Behandlung von Alopecia areata zu beginnen. Eine bemerkenswerte Lizenzvereinbarung mit WY Biotech wird voraussichtlich im Juni 2025 7,0 Millionen Dollar einbringen.
Zu den finanziellen Höhepunkten gehört die Beschaffung von 16,3 Millionen Dollar im Jahr 2024 durch verschiedene Transaktionen. Die Einnahmen sanken jedoch von 1,3 Millionen Dollar im Q4 2023 auf 394.000 Dollar im Q4 2024. Der Nettoverlust des Unternehmens stieg von 25,0 Millionen Dollar im Jahr 2023 auf 30,0 Millionen Dollar im Jahr 2024, was hauptsächlich auf Rechtskosten zurückzuführen ist.
Das Unternehmen sieht sich Herausforderungen bei der Nasdaq-Compliance gegenüber und muss die Zulassungsanforderungen bis April-Juni 2025 erfüllen. Das Management erkennt erhebliche Zweifel an der Fortführung der Geschäftstätigkeit ohne zusätzliche Finanzierung an, obwohl Finanzierungsaktivitäten mit Maxim Group als Platzierungsagent im Gange sind.
- FDA clearance received for Phase 1 trial of HCW9302 in alopecia areata
- New licensing deal with WY Biotech worth $7.0 million expected in June 2025
- Secured $20 million Equity Purchase Agreement with potential for additional $20 million
- R&D expenses decreased by 17% year-over-year to $6.4 million
- Net loss increased to $30.0 million in 2024 from $25.0 million in 2023
- Q4 2024 revenues declined 70% to $394,000 from $1.3 million in Q4 2023
- Legal expenses increased 142% to $15.9 million in 2024
- Substantial doubt about company's ability to continue as going concern without additional funding
- Risk of Nasdaq delisting if compliance requirements not met by June 2025
- Phase 2 clinical study for HCW9218 in ovarian cancer closed due to lack of enrollment
Insights
HCWB's financial situation is concerning, with the company explicitly stating substantial doubt regarding its ability to continue as a going concern without additional funding. The $30 million net loss for FY2024 represents a 20% deterioration from 2023's $25 million loss, despite cost-cutting measures. While revenues remained relatively stable at $2.6 million (down 7% from 2023), the company's financial position is increasingly precarious.
The staggering 142% increase in legal expenses to $15.9 million (from $6.6 million) significantly impacted overall performance. Adding to concerns, the company reported a $1.3 million loss due to fraud involving misdirection of funds. Their R&D spending decreased by 17% to $6.4 million, which may impact future pipeline development.
On the funding front, HCWB raised $16.3 million in 2024 through various mechanisms and secured an Equity Purchase Agreement potentially worth $40 million. The $7 million expected from WY Biotech in June 2025 provides some near-term relief, but the company faces imminent Nasdaq delisting if it doesn't regain compliance by April/June 2025 deadlines. A reverse stock split vote is scheduled to address this issue.
The company's survival hinges entirely on successful execution of additional capital-raising activities planned for first half 2025. Without this funding, management acknowledges they'll need to revise business plans and further reduce costs, putting development programs at risk.
HCWB's clinical and development pipeline shows mixed signals. The FDA clearance for a Phase 1 trial of HCW9302 in alopecia areata represents their first entry into autoimmune diseases, potentially expanding their therapeutic approach beyond oncology. The mechanism targeting regulatory T cell expansion is scientifically sound for autoimmune conditions.
However, the closure of their Phase 2 ovarian cancer study for HCW9218 due to lack of enrollment represents a significant setback in their oncology program. Patient recruitment challenges often indicate protocol design issues or competition from other trials with more promising candidates.
Their new TRBC platform with 50 proprietary compounds targeting hematologic/solid tumors shows preclinical promise, particularly in the competitive immune cell engager space. Their focus on improving CAR-T therapies through cost reduction and in-vivo manufacturing approaches aligns with industry trends toward more accessible cell therapies.
The licensing deal with WY Biotech for HCW11-006 with worldwide rights (while maintaining opt-in rights for Americas) represents a strategic asset monetization while preserving future commercialization options. However, the reduction in R&D spending by 17% raises questions about their ability to advance these preclinical assets toward clinical development.
Overall, while their scientific approach remains promising, financial constraints may significantly hamper their ability to advance these programs, particularly without substantial partnership support.
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024.
Dr. Hing Wong, Founder and CEO, stated, “We are more passionate than ever about our desire to create breakthrough immunotherapeutic treatments for diseases with no known cures, especially pancreatic, ovarian cancer and other age-related diseases. We have received clearance to begin clinical trials in alopecia areata, our first-quality-of-life indication, with one of our lead molecules, HCW9302. In non-human primate studies, HCW9302 is well tolerated at the dose level of effectively expanding regulatory T (“Treg”) cells. Our surrogate efficacious marker for HCW9302 in treated patients is the expansion of Treg cells after subcutaneous administration.”
Further, Dr. Wong provided insights to the Company’s preclinical programs, adding, “Our preclinical programs are also promising. In the fourth quarter of 2024, the Company revealed its new drug discovery and development platform, with a novel scaffolding or “backbone” of proteins called T-cell Receptor β Chain constant region (“TRBC”). The TRBC drug discovery and development platform leverages the Company’s in-depth knowledge of T cell and natural killer (“NK”) cell immunology. The Company has constructed 50 proprietary compounds with the TRBC platform for the treatment of hematologic and solid tumors, virally infected cells, and cellular senescence diseases associated with aging.”
Dr. Wong explained, “Our expanded portfolio now includes constructs with immune-cell engagers targeting cell-surface antigens associated with diseased cells and multifunctional immunotherapeutic fusions which improve the performance of immune checkpoint inhibitors. They exhibit remarkably target-specific anti-tumor activity and tolerability in relevant animal models.” He continued, “We believe that some of our TRBC-based molecules could be a game-changer for Cell and Gene Based Therapies (“CGTs”) by significantly reducing cost and improving the clinical efficacy of engineered effector cells for CGT. Based on preclinical studies, it appears they also support the rapidly developing “in-vivo” CAR-T manufacturing approach for CGT. We are excited to share the data in future scientific publications and invited presentations. We believe that we are uniquely positioned for a strong clinical development pipeline through our own programs and with corporate partnerships.”
Business Highlights
Business Development Transactions
- The Company’s clinical development strategy is to select certain proprietary molecules for development through out-licensing arrangements and other business development transactions. The Company continually assesses its portfolio of molecules in order to identify potential business development opportunities.
- On November 17, 2024, the Company entered an exclusive worldwide licensing agreement with WY Biotech Co. Ltd. (“WY Biotech”), which was amended in 2025. Under the amended agreement, the Company expects to receive
$7.0 million in June 2025. The WY Biotech license agreement grants WY Biotech the exclusive, world-wide license to use and apply HCW11-006 for in vivo applications. HCW11-006 is a preclinical drug. Under the terms of the license agreement, the Company has opt-in rights to reclaim the Americas market, including United States, Canada, Central America, and South America, at no cost which may be exercised after WY Biotech completes a Phase 1 clinical trial. - The next major business development program will focus on Immune-Cell Engagers, including T-Cell Engagers. In light of recent transactions demonstrating the strong interest in this class of therapeutics by larger pharmaceutical with the necessary clinical development expertise, the Company intends to develop these molecules through corporate partnering and out-licensing arrangements.
Financing Transactions
- In 2024, the Company raised
$16.3 million :
- On February 20, 2024, it raised
$2.5 million in a private placement of common stock with officers and directors. - In multiple closings throughout 2024, it raised
$6.9 million in Senior Notes, which are secured by the Company’s shares of Wugen common stock. The Company received shares of Wugen stock as an upfront licensing fee for the Wugen exclusive worldwide license for some of the Company’s proprietary molecules. - On November 18, 2024, the Company entered a
$6.9 million securities purchase agreement with an institutional investor, involving a registered direct offering and a concurrent private placement of common stock and warrants.
- On February 20, 2024, it raised
- On February 20, 2025, the Company entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC - Series 4 (“Square Gate”), pursuant to which the Company will have the right, but not the obligation, to sell to Square Gate, and Square Gate will have the obligation to purchase from the Company, up to
$20,000,000 (with a potential increase of an additional$20,000,000) worth of the Company’s shares of common stock, at the Company’s sole discretion, over the next 36 months, subject to certain conditions precedent and other limitations.
Compliance with Nasdaq Listing Rules
- During 2024, the Company received three deficiency notices from the Listing Staff of The Nasdaq Stock Market (the “Exchange”) related to the Company’s stock price of trading shares and the market value of the Company. On March 3, 2025, the Nasdaq Hearings Panel (the “Panel”) granted the Company an extension in which to regain compliance with all Nasdaq continued listing rules. As a result of the extension, the Panel granted the Company’s request for continued listing on the Exchange, provided that the Company demonstrates compliance with the Bid Price Rule by April 28, 2025, and all other Exchange continued listing rules by June 15, 2025.
- On March 31, 2025, the Company will hold a Special Meeting of the Stockholders to obtain stockholder approval for three proposals critical for the success of the compliance plan presented to the Panel, including a reverse stock split, use of the full line of the Equity Line of Credit, and approval of the terms to convert the Senior Notes issued in 2024 into equity.
Clinical Development Results
- On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments.
- As of December 31, 2024, the Company was required to close the Phase 2 clinical study to evaluate HCW9218 in combination with neoadjuvant chemotherapy in ovarian cancer sponsored by the University of Pittsburgh Medical Center, as required under the Settlement Agreement, due to lack of enrollment.
Financial Results
- Revenues: Revenues for the fourth quarters ended December 31, 2023 and 2024 were
$1.3 million and$394,000 , respectively. Revenues for the years ended December 31, 2023 and 2024 were$2.8 million and$2.6 million , respectively. Revenues in both periods were derived exclusively from the sale of licensed molecules to the Company’s licensee, Wugen. The licensed molecules are one of the components used by Wugen in manufacturing their immunotherapeutic products. - Research and development (R&D) expenses: R&D expenses for the fourth quarters ended December 31, 2023 and 2024 were
$2.1 million and$1.0 million , respectively, a decrease of$1.1 million , or51% . R&D expenses for the years ended December 31, 2023 and 2024 were$7.7 million and$6.4 million , respectively, a decrease of$1.3 million , or17% . R&D expenses were comparatively higher in the reporting periods of 2023 because there were two ongoing clinical trials to evaluate HCW9218 in cancer indications, and IND-enabling studies required for the IND application for HCW9302, including toxicology studies. For the year ended December 31, 2024, the decrease in R&D expenses compared to the comparable period in 2023 was partially offset by an increase in manufacturing costs for replenishing supply of the high-expressing cell line of HCW9101. - General and administrative (G&A) expenses: G&A expenses for the quarters ended December 31, 2023 and 2024 were
$1.7 million and$2.0 million , respectively, an increase of$367,320 , or22% . G&A expenses for the years ended December 31, 2023 and 2024 were$6.8 million and$6.8 million , respectively, an increase of$60,081 , or1% . Changes in G&A expenses reflect cost cutting measures effected by the Company in the second quarter of 2024, offset by increases in professional fees, facilities and office expenses, and financing expenses. - Legal expenses: Legal expenses for the quarter ended December 31, 2023 and 2024 were
$2.0 million and$148,949 , respectively, a decrease of$1.8 million , or92% . Legal expenses for the twelve months ended December 31, 2023 and 2024 were$6.6 million and$15.9 million , respectively, an increase of$9.3 million , or142% . The increase in legal expenses related to preparation of testimony and evidence for the hearing and the hearing itself in connection to the Arbitration with ImmunityBio and its affiliates. On July 13, 2024, the parties entered into a Settlement Agreement and General Release, and the Arbitration and related Complaint were dismissed on December 24, 2024. The Company is engaged in discussions with the law firms involved with this matter to arrange a reasonable payment plan with respect to those legal fees. - Reserve for credit losses and other expenses: In the year ended December 31, 2023, the Company recognized a reserve for credit losses related to a
$5.3 million interest reserve deposit that was not refunded as required by the lender after the Company terminated their credit agreement. In the year ended December 31, 2024, the Company recognized a$1.3 million loss resulting from the misdirection of funds held in Company accounts to a fraudulent account controlled by a third party. - Net loss: Net loss for the fourth quarters ended December 31, 2023 and 2024 was
$10.7 million and$3.4 million , respectively. Net loss for the years ended December 31, 2023 and 2024 was$25.0 million and$30.0 million , respectively, including legal fees incurred in connection with the Arbitration discussed above.
Financial Guidance
As of December 31, 2024, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered future elements of our financing plan that were probable and likely to be implemented within the next year to determine if financing activities currently underway are sufficient to mitigate the substantial doubt in our going concern analysis. After launching a multi-step financing plan in the third quarter of 2024, we have completed financing transactions. We have additional capital-raising activities planned for the first half of 2025, for which Maxim Group LLC will act as our Placement Agent. If the Company is not successful in raising additional capital through these activities, management may need to revise its business plan and reduce costs.
About HCW Biologics
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular, diabetes, neurodegenerative, and autoimmune diseases, as well as other inflammatory conditions. The Company has combined a deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop two drug discovery platforms, each with a novel backbone which is used to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. The Company’s legacy drug discovery platform is its TOBI™ (Tissue factOr-Based fusIon) discovery platform, which has a Tissue-Factor based backbone. It was used to create HCW Biologics’ molecules: HCW9218, HCW9302, HCW9206 and HCW9201. HCW9302 is a clinical-stage molecule, cleared by the FDA to be evaluated in patients with an autoimmune disorder. The Company’s second generation drug discovery and development platform, called the T-cell Receptor β Chain constant region (“TRBC”) platform, uses a unique protein-based backbone. Immunotherapeutics created with the Company’s two distinct drug discovery platforms have different characteristics and mechanisms of action, expanding the various pathways for treating senescence-associated disorders.
Forward Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include: the Company’s ability to develop new immunotherapeutic treatments for non-oncology or oncology indications; timing of initiation of studies for age-related diseases; the Company’s ability to continue as a going concern and that after considering the elements of the Company’s financing plan that were probable to occur within a year of the date of issuance, the Company concluded that substantial doubt was not alleviated in its going concern analysis; the Company’s cash runway; the Company’s expectations regarding future purchases of licensed molecules by Wugen; the Company’s ability to finalize the license of a preclinical molecule; the initiation of patient enrollment for clinical trial to evaluate HCW9302; the Company’s future capital-raising plans and ability to continue with clinical development efforts until they are achieved, if at all; and Company’s ability to pay legal fees incurred in connection with the arbitration with ImmunityBio and its affiliates. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025 and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
| HCW Biologics Inc. Statements of Operations | ||||||||||||||||||
| For the Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||
| 2023 | 2024 | 2023 | 2024 | |||||||||||||||
| Revenues: | Unaudited | Audited | ||||||||||||||||
| Revenues | $ | 1,324,003 | $ | 394,804 | $ | 2,841,794 | $ | 2,566,792 | ||||||||||
| Cost of revenues | (1,071,357 | ) | (315,843 | ) | (2,281,434 | ) | (1,607,389 | ) | ||||||||||
| Net revenues | 252,646 | 78,961 | 560,360 | 959,403 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | 2,136,397 | 1,049,611 | 7,676,316 | 6,388,994 | ||||||||||||||
| General and administrative | 1,672,840 | 2,040,160 | 6,779,515 | 6,839,596 | ||||||||||||||
| Legal expenses | 1,961,599 | 148,949 | 6,571,689 | 15,910,480 | ||||||||||||||
| Reserve for credit losses and other expenses | 5,250,000 | — | 5,250,000 | 1,300,000 | ||||||||||||||
| Total operating expenses | 11,020,836 | 3,238,720 | 26,277,520 | 30,439,070 | ||||||||||||||
| Loss from operations | (10,768,190 | ) | (3,159,759 | ) | (25,717,160 | ) | (29,479,667 | ) | ||||||||||
| Interest expense | — | (248,107 | ) | (283,042 | ) | (631,137 | ) | |||||||||||
| Other income, net | 87,660 | 34,593 | 1,005,925 | 86,990 | ||||||||||||||
| Net loss | $ | (10,680,530 | ) | $ | (3,373,273 | ) | $ | (24,994,277 | ) | $ | (30,023,814 | ) | ||||||
| Net loss per share, basic and diluted | $ | (0.30 | ) | $ | (0.08 | ) | $ | (0.70 | ) | $ | (0.77 | ) | ||||||
| Weighted average shares outstanding, basic and diluted | 35,996,415 | 42,301,694 | 35,929,446 | 38,793,018 | ||||||||||||||
| HCW Biologics Inc. Audited Balance Sheets | |||||||||
| December 31, | December 31, | ||||||||
| 2023 | 2024 | ||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 3,595,101 | $ | 4,674,572 | |||||
| Accounts receivable, net | 1,535,757 | 582,201 | |||||||
| Prepaid expenses | 1,042,413 | 328,181 | |||||||
| Other current assets | 230,916 | 113,528 | |||||||
| Total current assets | 6,404,187 | 5,698,482 | |||||||
| Investments | 1,599,751 | 1,599,751 | |||||||
| Property, plant and equipment, net | 20,453,184 | 22,909,869 | |||||||
| Other assets | 56,538 | 28,476 | |||||||
| Total assets | $ | 28,513,660 | $ | 30,236,578 | |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||||
| Liabilities | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 6,167,223 | $ | 22,332,261 | |||||
| Accrued liabilities and other current liabilities | 2,580,402 | 981,940 | |||||||
| Short-term debt, net | — | 6,314,684 | |||||||
| Total current liabilities | 8,747,625 | 29,628,885 | |||||||
| Debt, net | 6,304,318 | 7,377,865 | |||||||
| Total liabilities | 15,051,943 | 37,006,750 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders’ equity (deficit): | |||||||||
| Common stock: | |||||||||
| Common, and 36,025,104 shares issued at December 31, 2023; 250,000,000 shares authorized and 44,541,295 shares issued at December 31, 2024 | 3,603 | 4,454 | |||||||
| Additional paid-in capital | 83,990,437 | 93,781,511 | |||||||
| Accumulated deficit | (70,532,323 | ) | (100,556,137 | ) | |||||
| Total stockholders’ equity (deficit) | 13,461,717 | (6,770,172 | ) | ||||||
| Total liabilities and stockholders’ equity (deficit) | $ | 28,513,660 | $ | 30,236,578 | |||||
----
FAQ
What is the expected revenue from HCW Biologics' licensing deal with WY Biotech?
How much capital did HCWB raise in 2024?
What are the Nasdaq compliance deadlines for HCWB stock?
What was HCWB's net loss for fiscal year 2024?
What clinical trial progress has HCWB made with HCW9302?
